A Long-Term Study of Prognosis in Monoclonal Gammopathy of Undetermined Significance
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited. METHODS: We identified 1384 patients residing in southeastern Minnesota in whom MGUS was diagnosed at the Mayo Clinic from 1960 through 1994. The primary end point was progression to multiple myeloma or another plasma-cell cancer. RESULTS: During 11,009 person-years of follow-up, MGUS progressed in 115 of the 1384 patients to multiple myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma (relative risk of progression, 25.0, 2.4, 8.4, 46.0, 0.9, and 8.5, respectively). The overall relative risk of progression was 7.3 in these patients as compared with the white population of the Iowa Surveillance, Epidemiology, and End Results program. In 32 additional patients, the monoclonal protein concentration increased to more than 3 g per deciliter or the percentage of plasma cells in the bone marrow increased to more than 10 percent (smoldering multiple myeloma) but without progression to overt myeloma or related disorders. The cumulative probability of progression was 12 percent at 10 years, 25 percent at 20 years, and 30 percent at 25 years. The initial concentration of serum monoclonal protein was a significant predictor of progression at 20 years. CONCLUSIONS: The risk of progression of MGUS to multiple myeloma or related disorders is about 1 percent per year.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“MGUS progresses to multiple myeloma or related malignancy a rate of 1% per year.16,17”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [16]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Gooley, T. A., Leisenring, W., Crowley, J., & Storer, B. E. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19990330)18:6<695::aid-sim60>3.0.co;2-o · Cited by 2,688
History of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443
Self-citationKyle, R., Linos, A., Beard, C., Linke, R., Gertz, M., O'Fallon, W., & Kurland, L. (1992) · Blood · doi:10.1182/blood.v79.7.1817.1817 · Cited by 657
Self-citationMonoclonal gammopathy of undetermined significance
Kyle, R. A. (1978) · The American Journal of Medicine · doi:10.1016/0002-9343(78)90522-3 · Cited by 607
Self-citationFrequency of Pathological Proteins (M‐components) in 6,995 Sera from an Adult Population
AXELSSON, U., BACHMANN, R., & HÄLLÉN, J. (1966) · Acta Medica Scandinavica · doi:10.1111/j.0954-6820.1966.tb05453.x · Cited by 436
“Benign” Monoclonal Gammopathy—After 20 to 35 Years of Follow-Up
KYLE, R. A. (1993) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60015-9 · Cited by 338
Self-citationThe Analysis of Mortality by the Subject-Years Method
Berry, G. (1983) · Biometrics · doi:10.2307/2530817 · Cited by 278
Research works printed but not linked: 4
- Hallen J, 1966, Acta Med Scand Suppl, 462, 1
- Kyle RA, Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of clinical laboratory immunology. 5th ed. Washington, D.C.: ASM Press, 1997:156-76.
- Kyle RA, 1999, Blood, 94, 537a
- Fonseca R, 1999, Blood, 94, 663a
Cited by
Items 101–200 of 1,000
Neurological aspects of multiple myeloma and related disorders
Dispenzieri, A., & Kyle, R. A. (2005) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2005.01.024 · Cited by 161
Self-citationLandgren, O., Kyle, R. A., Hoppin, J. A., Beane Freeman, L. E., Cerhan, J. R., Katzmann, J. A., Rajkumar, S. V., & Alavanja, M. C. (2009) · Blood · doi:10.1182/blood-2009-02-203471 · Cited by 166
Self-citationThe Complexity and Heterogeneity of Monoclonal Immunoglobulin–Associated Renal Diseases
Sethi, S., Rajkumar, S. V., & D’Agati, V. D. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017121319 · Cited by 163
Self-citationMitsiades, C. S., Mitsiades, N., Munshi, N. C., & Anderson, K. C. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.10.020 · Cited by 166
Monoclonal Gammopathy–Associated Peripheral Neuropathy: Diagnosis and Management
Chaudhry, H. M., Mauermann, M. L., & Rajkumar, S. V. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.003 · Cited by 164
Self-citationMyeloma today: Disease definitions and treatment advances
Rajkumar, S. V. (2016) · American Journal of Hematology · doi:10.1002/ajh.24236 · Cited by 160
“SMM carries a much higher risk of progression to malignancy (approximately 10% per year) than MGUS (approximately 1% per year) [12,13].”
BackgroundSelf-citationCommon variation at 3p22.1 and 7p15.3 influences multiple myeloma risk
Broderick, P., Chubb, D., Johnson, D. C., Weinhold, N., Försti, A., Lloyd, A., Olver, B., Ma, Y. P., Dobbins, S. E., Walker, B. A., et al. (2012) · Nature Genetics · doi:10.1038/ng.993 · Cited by 163
“Monoclonal gammopathy of undetermined significance (MGUS; a pre-malignant clone of plasma cells producing a monoclonal paraprotein) is present in ∼2% of individuals older than 50 years, and the risk of progressing to multiple myeloma increases by 1% each yea”
BackgroundFracture Risk in Monoclonal Gammopathy of Undetermined Significance
Melton, L. J., Rajkumar, S. V., Khosla, S., Achenbach, S. J., Oberg, A. L., & Kyle, R. A. (2004) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.0301212 · Cited by 161
“After approval by Mayo’s Institutional Review Board, we used this unique database (the Rochester Epidemiology Project) to identify the 1384 patients who resided in southeastern Minnesota when they were first diagnosed with MGUS in 1960–1994.((17)) The present analysis was restricted to the subset of 514 patients who r…”
BackgroundMethodInfluentialSelf-citationMultiple myeloma: 2013 update on diagnosis, risk‐stratification, and management
Rajkumar, S. V. (2013) · American Journal of Hematology · doi:10.1002/ajh.23390 · Cited by 159
Self-citationRossi, D., Sozzi, E., Puma, A., Paoli, L. D., Rasi, S., Spina, V., Gozzetti, A., Tassi, M., Cencini, E., Raspadori, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07711.x · Cited by 172
Dissecting racial disparities in multiple myeloma
Marinac, C. R., Ghobrial, I. M., Birmann, B. M., Soiffer, J. L., & Rebbeck, T. R. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0284-7 · Cited by 169
Vachon, C. M., Kyle, R. A., Therneau, T. M., Foreman, B. J., Larson, D. R., Colby, C. L., Phelps, T. K., Dispenzieri, A., Kumar, S. K., Katzmann, J. A., et al. (2009) · Blood · doi:10.1182/blood-2008-12-192575 · Cited by 152
Self-citationCurrent Concepts in the Evaluation of Multiple Myeloma with MR Imaging and FDG PET/CT
Hanrahan, C. J., Christensen, C. R., & Crim, J. R. (2010) · Radiographics · doi:10.1148/rg.301095066 · Cited by 162
Multiple myeloma: 2011 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2011) · American Journal of Hematology · doi:10.1002/ajh.21913 · Cited by 152
Self-citationBarrell, K., & Smith, A. G. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.006 · Cited by 165
López-Corral, L., Gutiérrez, N. C., Vidriales, M. B., Mateos, M. V., Rasillo, A., García-Sanz, R., Paiva, B., & San Miguel, J. F. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1066 · Cited by 149
“Thus, whereas MGUS evolves to MM or a related malignancy at a rate of 1% per year (1), the cumulative probability of progression to active MM or amyloidosis in SMM is 10% per year in the first 5 years (6).”
BackgroundSigurdardottir, E. E., Turesson, I., Lund, S. H., Lindqvist, E. K., Mailankody, S., Korde, N., Björkholm, M., Landgren, O., & Kristinsson, S. Y. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.23 · Cited by 160
How I manage monoclonal gammopathy of undetermined significance
Go, R. S., & Rajkumar, S. V. (2018) · Blood · doi:10.1182/blood-2017-09-807560 · Cited by 141
“There are 3 subtypes of MGUS namely IgM MGUS, non-IgM MGUS, and light chain MGUS, each with distinct rate and type of progression (Table 1).(8,9) MGUS is of considerable clinical importance due to its high prevalence in the general population, the persistent risk of progression to LPM, its known causal association wit…”
BackgroundSelf-citationSmoldering multiple myeloma: natural history and recognition of an evolving type
Rosiñol, L., Bladé, J., Esteve, J., Aymerich, M., Rozman, M., Montoto, S., Giné, E., Nadal, E., Filella, X., Queralt, R., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04654.x · Cited by 151
“In fact, the clinical and biological behaviour of the latter condition would be comparable with MGUS, but with a higher plasma cell burden and, in consequence, with a higher probability of evolution to symptomatic MM (Kyle et al, 2002, Montoto et al, 2002).”
BackgroundEpidemiology of the plasma-cell disorders
Kyle, R. A., & Rajkumar, S. V. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.08.001 · Cited by 169
Self-citationJolles, S. R. A., Chapel, H. M., & Litzman, J. (2016) · Clinical & Experimental Immunology · doi:10.1111/cei.12915 · Cited by 160
Waldenström macroglobulinaemia
Ghobrial, I. M., Gertz, M. A., & Fonseca, R. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01246-4 · Cited by 145
Turesson, I., Kovalchik, S. A., Pfeiffer, R. M., Kristinsson, S. Y., Goldin, L. R., Drayson, M. T., & Landgren, O. (2014) · Blood · doi:10.1182/blood-2013-05-505487 · Cited by 141
“The average risk of progression is estimated to be 1%/yr, and the 25-year cumulative risk is 30%.(11,12) However, there is considerable variation in the risk of progression, and differentiating low-risk patients, who may not need further follow-up, from high-risk patients, who may warrant close monitoring or enrolment…”
BackgroundResultMultiple myeloma: 2012 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2012) · American Journal of Hematology · doi:10.1002/ajh.22237 · Cited by 144
Self-citationPrognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance
Kumar, S. K., Rajkumar, S. V., Kyle, R. A., Lacy, M. Q., Dispenzieri, A. A., Fonseca, R., Lust, J. A., Gertz, M. A., Greipp, P. R., & Witzig, T. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.159 · Cited by 160
Self-citationImmunophenotyping in multiple myeloma and related plasma cell disorders
Kumar, S. K., Kimlinger, T. K., & Morice, W. G. (2010) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2010.09.002 · Cited by 154
“70 Although the presence of t(11;14) is associated with better outcome in patients with myeloma, the expression of CD20 does not appear to have any prognostic impact.”
BackgroundDNA methylation as a transcriptional regulator of the immune system
Morales‐Nebreda, L., McLafferty, F. S., & Singer, B. D. (2018) · Translational research · doi:10.1016/j.trsl.2018.08.001 · Cited by 161
Laubach, J., Richardson, P., & Anderson, K. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070209-175325 · Cited by 139
Bird, J. M., Behrens, J., Westin, J., Turesson, I., Drayson, M. T., Beetham, R., D’Sa, S., Soutar, R. L., Waage, A., Gulbrandsen, N., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07807.x · Cited by 153
“In a study of 1384 individuals diagnosed with MGUS in south-eastern Minnesota between 1960 and 1994, monoclonal light chain was detected in the urine in 31% patients (10% lambda; 21% kappa) by immunofixation (Kyle et al, 2002).”
BackgroundInfluentialDutta, A. K., Fink, J. L., Grady, J. P., Morgan, G. J., Mullighan, C. G., To, L. B., Hewett, D. R., & Zannettino, A. C. W. (2019) · Leukemia · doi:10.1038/s41375-018-0206-x · Cited by 136
The myelodysplastic syndrome(s): a perspective and review highlighting current controversies
Steensma, D. P., & Tefferi, A. (2003) · Leukemia Research · doi:10.1016/s0145-2126(02)00098-x · Cited by 152
“[52] Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al.”
BackgroundKhoór, A., & Colby, T. V. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0102-ra · Cited by 140
“It may be preceded by monoclonal gammopathy of undetermined significance and may occur in association with other plasma cell dyscrasias, such as multiple myeloma and Waldenström macroglobulinemia.(14) Elderly men are more commonly affected than other demographic groups.”
BackgroundAcquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma
Ma, C. X., Lacy, M. Q., Rompala, J. F., Dispenzieri, A. A., Rajkumar, S. V., Greipp, P. R., Fonseca, R., Kyle, R. A., & Gertz, M. A. (2004) · Blood · doi:10.1182/blood-2003-10-3400 · Cited by 138
Self-citationFowler, J. A., Lwin, S. T., Drake, M. T., Edwards, J. R., Kyle, R. A., Mundy, G. R., & Edwards, C. M. (2011) · Blood · doi:10.1182/blood-2011-01-330407 · Cited by 136
Self-citationWaldenström macroglobulinaemia
Fonseca, R., & Hayman, S. R. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06724.x · Cited by 138
“These patients have 46 times greater risk of developing WM than the general population (Kyle et al, 2002).”
BackgroundTherneau, T. M., Kyle, R. A., Melton, L. J., Larson, D. R., Benson, J. T., Colby, C. L., Dispenzieri, A. A., Kumar, S. K., Katzmann, J. A., Cerhan, J. R., et al. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.06.014 · Cited by 149
Self-citationTargeting MYC in multiple myeloma
Jovanović, K., Roche‐Lestienne, C., Ghobrial, I. M., Facon, T. T. F., Quesnel, B., & Manier, S. (2018) · Leukemia · doi:10.1038/s41375-018-0036-x · Cited by 142
“The premalignant MGUS stage precedes MM in almost all patients [3, 4] and has a progression rate of 1% per year [32].”
Sanoja-Flores, L., Flores-Montero, J. A., Garcés, J., Paiva, B., Puig, N., García‐Mateo, A., García-Sánchez, O., Corral-Mateos, A., Burgos, L., Blanco, E., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0153-9 · Cited by 144
Biology and therapy of multiple myeloma
Joshua, D., Bryant, C. E., Dix, C. H. K., Gibson, J., & Ho, P. J. (2019) · The Medical Journal of Australia · doi:10.5694/mja2.50129 · Cited by 143
Marti, G. E., Carter, P., Abbasi, F., Washington, G. C., Jain, N., Zenger, V. E., Ishibe, N., Goldin, L. R., Fontaine, L. S., Weissman, N., et al. (2003) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.10013 · Cited by 144
“A median of 10 years is required for MGUS to convert to MM (17,18).”
BackgroundMalignancies and monoclonal gammopathy in G aucher disease; a systematic review of the literature
Arends, M. L., van Dussen, L., Biegstraaten, M., & Hollak, C. E. M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12335 · Cited by 131
“Progression from MGUS to MM is seen in about 1% per year (Kyle et al, 2002) in the general popu- lation.”
BackgroundPathophysiology and treatment of systemic amyloidosis
Gillmore, J. D., & Hawkins, P. N. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.171 · Cited by 143
C3 glomerulopathy associated with monoclonal Ig is a distinct subtype
Ravindran, A., Fervenza, F. C., Smith, R. J., & Sethi, S. M. (2018) · Kidney International · doi:10.1016/j.kint.2018.01.037 · Cited by 136
Single-cell profiling of tumour evolution in multiple myeloma — opportunities for precision medicine
Dutta, A. K., Alberge, J.-B., Sklavenitis‐Pistofidis, R., Lightbody, E. D., Getz, G. A., & Ghobrial, I. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00593-y · Cited by 142
Rajkumar, S. V., Kyle, R. A., & Buadi, F. K. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0520 · Cited by 143
“MGUS is important to clinicians because it is associated with a 1% per year risk of progression to multiple myeloma (MM) or related malignancy.(3) It is also important because it is found incidentally during the work-up of a variety of symptoms and disorders, and has confirmed and reported associations with numerous d…”
BackgroundMethodSelf-citationA validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS
Chng, W. J. (2005) · Blood · doi:10.1182/blood-2005-02-0761 · Cited by 127
Thrombotic microangiopathy associated with monoclonal gammopathy
Ravindran, A., Go, R. S., Fervenza, F. C., & Sethi, S. M. (2016) · Kidney International · doi:10.1016/j.kint.2016.09.045 · Cited by 127
Bäuerle, T., Hillengaß, J., Fechtner, K., Zechmann, C. M., Grenacher, L., Moehler, T. M., Heiß, C., Barbara, W.-G., Neben, K., Kauczor, H., et al. (2009) · Radiology · doi:10.1148/radiol.2522081756 · Cited by 127
Critical roles for immunoglobulin translocations and cyclin D dysregulation in multiple myeloma
Bergsagel, P. L., & Kuehl, W. M. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00052.x · Cited by 125
“However, prolonged follow up of a large group of MGUS subjects at the Mayo Clinic has shown that about 1% per year of patients with non-IgM MGUS progress to develop symptomatic MM (3).”
BackgroundPérez‐Persona, E., Mateo, G., García‐Sanz, R., Mateos, M., De Las Heras, N., De Coca, A. G., Hernández, J. M., Galende, J., Martín‐Nuñez, G., Bárez, A., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07929.x · Cited by 125
“Several reports identified factors for progression in both entities (Weber et al, 1997; Cesana et al, 2002; Kyle et al, 2002; Rajkumar, 2005) and recently, Rosiñol et al (2003, 2005) described evolving and”
BackgroundMcKenna, R. W., & Kroft, S. H. (2011) · Elsevier eBooks · doi:10.1016/b978-0-7216-0040-6.00025-3 · Cited by 125
Monoclonal gammopathy of undetermined significance: a consensus statement
Berenson, J. R., Anderson, K. C., Audell, R. A., Boccia, R. V., Coleman, M., Dimopoulos, M. A., Drake, M. T., Fonseca, R., Harousseau, J., Joshua, D., et al. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08207.x · Cited by 134
“Half of the panel argued that only MGUS patients with higher levels of M-proteins (>15 g/l) and abnormal FLC ratios should undergo these procedures, as they are more likely to have MM or another serious B-cell disorder (Kyle et al, 2002).”
BackgroundInfluentialSelf-citationMonoclonal gammopathies of undetermined significance: a review
Kyle, R. A., & Rajkumar, S. V. (2003) · Immunological Reviews · doi:10.1034/j.1600-065x.2003.00056.x · Cited by 135
“09 0 8 17 30 Modified from (21), by permission of the Massachusetts Medical Society.”
BackgroundInfluentialSelf-citationCapillary electrophoresis and its application in the clinical laboratory
Petersen, J. R., Okorodudu, A. O., Mohammad, A. A., & Payne, D. A. (2003) · Clinica Chimica Acta · doi:10.1016/s0009-8981(03)00006-8 · Cited by 143
Cancer Incidence among Pesticide Applicators Exposed to Permethrin in the Agricultural Health Study
Rusiecki, J. A., Patel, R., Koutros, S., Freeman, L. E. B., Landgren, O., Bonner, M. R., Coble, J., Lubin, J. H., Blair, A. E., Hoppin, J. A., et al. (2008) · Environmental Health Perspectives · doi:10.1289/ehp.11318 · Cited by 121
“MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management.”
BackgroundInfluentialIwanaga, M., Tagawa, M., Tsukasaki, K., Kamihira, S., & Tomonaga, M. (2007) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)61090-2 · Cited by 121
Real-Time Monitoring of a Protein Biomarker
Parolo, C., Idili, A., Ortega, G., Csordas, A. T., Hsu, A., Arroyo‐Currás, N., Yang, Q., Ferguson, B. S., Wang, J., & Plaxco, K. W. (2020) · ACS Sensors · doi:10.1021/acssensors.0c01085 · Cited by 124
Monoclonal gammopathy: significance and possible causality in renal disease
Paueksakon, P., Revelo, M. P., Horn, R. G., Shappell, S. B., & Fogo, A. B. (2003) · American Journal of Kidney Diseases · doi:10.1016/s0272-6386(03)00412-8 · Cited by 119
Autoimmunity and lymphomagenesis
Goldin, L. R., & Landgren, O. (2008) · International Journal of Cancer · doi:10.1002/ijc.24141 · Cited by 118
The Genetic Architecture of Multiple Myeloma
Prideaux, S. M., O’Brien, E. C., & Chevassut, T. J. T. (2014) · Advances in Hematology · doi:10.1155/2014/864058 · Cited by 130
“MGUS has a prevalence of >5% in adults aged over 70 and a progression risk to myeloma quantified at 1% per year [2, 3].”
BackgroundDifferential diagnosis of monoclonal gammopathy of undetermined significance
Merlini, G., & Palladini, G. O. (2012) · Hematology · doi:10.1182/asheducation.v2012.1.595.3798563 · Cited by 123
Condomines, M., Hose, D., Raynaud, P., Hundemer, M., Vos, J. D., Baudard, M., Moehler, T. M., Pantesco, V., Moos, M., Schved, J., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.3307 · Cited by 129
“1% (48) and these data may suggest initiating vaccination strategies early in these patients, i.”
Kristinsson, S. Y., Björkholm, M., Andersson, T., Eloranta, S., Dickman, P. W., Goldin, L. R., Blimark, C. H., Mellqvist, U., Wåhlin, A., Turesson, I., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.010066 · Cited by 129
“Indeed, long-term follow-up of MGUS patients reveals an average 1% annual risk of developing lymphoproliferative malignancies.(5,6) Additional data suggest that MGUS patients with an abnormal serum κ-λ free light chainratio, non-IgG MGUS and a high serum M-protein level (>1.”
BackgroundResultInfluentialCirculating Serum Free Light Chains As Predictive Markers of AIDS-Related Lymphoma
Landgren, O., Goedert, J. J., Rabkin, C. S., Wilson, W. H., Dunleavy, K. M., Kyle, R. A., Katzmann, J. A., Rajkumar, S. V., & Engels, E. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1322 · Cited by 122
Self-citationKyle, R. A., & Rajkumar, S. V. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06873.x · Cited by 130
“The size of the M protein at the time of diagnosis of MGUS was the most important predictor of progression in 1384 patients with MGUS (Kyle et al, 2002).”
BackgroundInfluentialSelf-citationBladé, J., Dimopoulos, M., Rosiñol, L., Rajkumar, S. V., & Kyle, R. A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.2257 · Cited by 115
“Patients with MGUS have an M-protein concentration of less than 3 g/dL with no substantial amount of light chain in the urine, less than 10% BMPC plus the absence of skeletal involvement, anemia, hypercalcemia, or renal insufficiency that can be attributed the clonal plasma-cell proliferative disorder.(15,16) When the…”
Self-citationKatzmann, J. A., Clark, R., Kyle, R. A., Larson, D. R., Therneau, T. M., Melton, L. J., Benson, J. T., Colby, C. L., Dispenzieri, A., Landgren, O., et al. (2013) · Leukemia · doi:10.1038/leu.2012.189 · Cited by 109
Self-citationNon-Infectious Granulomatous Diseases of the Skin and their Associated Systemic Diseases
Hawryluk, E. B., Izikson, L., & English, J. C. (2010) · American Journal of Clinical Dermatology · doi:10.2165/11530080-000000000-00000 · Cited by 115
“In general, patients (without NXG) who have a paraproteinemia or monoclonal gammopathy of undetermined significance (MGUS) have a rate of progression to multiple myeloma of approximately 1% per year, or 25% at 20 years after diagnosis.([50]) ForNXGpatients, retrospective analyses indicate that 10–25% of patients with…”
Multiple myeloma: diagnosis and treatment.
Nau, K. C., & Lewis, W. D. (2008) · PubMed · Cited by 142
Kristinsson, S. Y., Tang, M., Pfeiffer, R. M., Björkholm, M., Blimark, C. H., Mellqvist, U., Wåhlin, A., Turesson, I., & Landgren, O. (2010) · Blood · doi:10.1182/blood-2010-04-282848 · Cited by 113
“5% per year.(4) While patients with MGUS are asymptomatic, they may have increased morbidity and mortality.”
BackgroundVallat, L. D., Benhamou, Y., Gutierrez, M., Ghillani‐Dalbin, P., Hercher, C., Thibault, V., Charlotte, F., Pietté, J. C., Poynard, T., Merle‐Béral, H., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20594 · Cited by 112
Greenberg, A. J., Vachon, C. M., & Rajkumar, S. V. (2012) · Leukemia · doi:10.1038/leu.2011.368 · Cited by 108
Self-citationMadan, S., Dispenzieri, A. A., Lacy, M. Q., Buadi, F. K., Hayman, S. R., Zeldenrust, S. R., Rajkumar, S. V., Gertz, M. A., & Kumar, S. K. (2010) · Mayo Clinic Proceedings · doi:10.4065/mcp.2009.0547 · Cited by 110
Self-citationSethi, S. M., Vriese, A. S. D., & Fervenza, F. C. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00461-5 · Cited by 128
Raja, K. R. M., Kovářová, L., & Hájek, R. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08121.x · Cited by 127
“Circulating PCs are found more frequently in MM – almost 80% of myeloma patients have detectable circulating PCs (Kyle et al, 2002).”
BackgroundInfluentialRespiratory tract infections and subsequent risk of chronic lymphocytic leukemia
Landgren, O., Rapkin, J. S., Caporaso, N. E., Mellemkjær, L., Gridley, G., Goldin, L. R., & Engels, E. A. (2006) · Blood · doi:10.1182/blood-2006-08-044008 · Cited by 110
Paiva, B., Montes, M.-C., García‐Sánz, R., Ocio, E. M., Alonso, J., Heras, N. D. L., Escalante, F., Cuello, R., de Coca, A. G., Galende, J., et al. (2013) · Leukemia · doi:10.1038/leu.2013.124 · Cited by 118
López‐Corral, L., Sarasquete, M. E., Beà, S., García‐Sánz, R., Mateos, M., Corchete, L. A., Sayagués, J. M., García, E., Bladé, J., Oriol, A., et al. (2012) · Leukemia · doi:10.1038/leu.2012.128 · Cited by 111
Monoclonal gammopathy of cutaneous significance: review of a relevant concept
Lipsker, D. M. (2016) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.13847 · Cited by 107
Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape
Gromova, M., Vaggelas, A., Dallmann, G., & Seimetz, D. (2020) · Biomarker Insights · doi:10.1177/1177271920974652 · Cited by 97
Barlogie, B., van Rhee, F., Shaughnessy, J. D., Epstein, J., Yaccoby, S., Pineda-Roman, M., Hollmig, K., Alsayed, Y., Hoering, A., Szymonifka, J., et al. (2008) · Blood · doi:10.1182/blood-2008-06-164228 · Cited by 102
Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma
Ria, R., Todoerti, K., Berardi, S., Coluccia, A. M. L., Luisi, A. D., Mattioli, M., Ronchetti, D., Morabito, F., Guarini, A., Petrucci, M. T., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0040 · Cited by 103
“Previous gene expression profiling studies designed to identify genes perhaps involved in the initiation and progression of multiple myeloma (10, 18) revealed that monoclonal gammopathy of undetermined significance and multiple myeloma plasma cells can be distinguished from normal plasma cells, whereas their own diffe…”
BackgroundMurray, D., Kumar, S. K., Kyle, R. A., Dispenzieri, A., Dasari, S., Larson, D. R., Vachon, C., Cerhan, J. R., & Rajkumar, S. V. (2019) · Blood Cancer Journal · doi:10.1038/s41408-019-0263-z · Cited by 102
Self-citationCancer statistics for African American and Black people, 2025
Saka, A. H., Giaquinto, A. N., McCullough, L. E., Tossas, K. Y., Star, J., Jemal, A., & Siegel, R. L. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21874 · Cited by 171
Lindqvist, E. K., Goldin, L. R., Landgren, O., Blimark, C. H., Mellqvist, U., Turesson, I., Wåhlin, A., Björkholm, M., & Kristinsson, S. Y. (2011) · Blood · doi:10.1182/blood-2011-04-347559 · Cited by 108
Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma
Au, G. G., Lincz, L. F., Enno, A., & Shafren, D. R. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06550.x · Cited by 108
“Up to 30% of MGUS patients progress to develop MM, however it is presently impossible to predict individual prognosis and so this benign dyscrasia is generally left untreated (Kyle et al, 2002).”
BackgroundMikulasova, A., Wardell, C. P., Murison, A., Boyle, E. M., Jackson, G. H., Smetana, J., Kufova, Z., Pour, L., Sandecka, V., Almasi, M., et al. (2017) · Haematologica · doi:10.3324/haematol.2017.163766 · Cited by 101
Witzig, T. E., Laumann, K. M., Lacy, M. Q., Hayman, S. R., Dispenzieri, A., Kumar, S., Reeder, C. B., Roy, V, Lust, J. A., Gertz, M. A., et al. (2013) · Leukemia · doi:10.1038/leu.2012.236 · Cited by 100
Self-citationRoss, F. M., Chiecchio, L., Dagrada, G., Protheroe, R. K. M., Stockley, D. M., Harrison, C. J., Cross, N. C. P., Szubert, A. J., Drayson, M. T., Morgan, G. J., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.016329 · Cited by 99
Monoclonal Gammopathy of Undetermined Significance
Bladé, J. (2006) · New England Journal of Medicine · doi:10.1056/nejmcp052790 · Cited by 114
MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management
Rajkumar, S. V. (2005) · Hematology · doi:10.1182/asheducation-2005.1.340 · Cited by 97
“7 (0-10) in amyloidosis, 3 (0-23) in MGUS, 4 (1-30) in SMM, 11 (1-48) in NMM, and 20 (6-47) in RMM, P < 0.”
Self-citationMonoclonal Gammopathy–Associated Proliferative Glomerulonephritis
Sethi, S. M., & Rajkumar, S. V. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.08.002 · Cited by 107
“It is associatedwith a risk of progression to multiple myeloma or related plasma cell malignancy, as well as to paraprotein-related disorders such as light chain amyloidosis.(1) Although, by definition, MGUS is a premalignant process, the secretedMprotein is often a functioning antibody and can thus be associated with…”
BackgroundSelf-citationMonoclonal gammopathy of undetermined significance
Mouhieddine, T. H., Weeks, L. D., & Ghobrial, I. M. (2019) · Blood · doi:10.1182/blood.2019846782 · Cited by 115
Schop, R. F. J., Wier, S. A. V., Xu, R., Ghobrial, I. M., Ahmann, G. J., Greipp, P. R., Kyle, R. A., Dispenzieri, A. A., Lacy, M. Q., Rajkumar, S. V., et al. (2006) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2006.04.009 · Cited by 99
Self-citationLymphoplasmacytic lymphoma–Waldenstrom's macroglobulinemia
Vitolo, U., Ferreri, A. J. M., & Montoto, S. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.03.008 · Cited by 97
“[20] Kyle RA, Therneau TM, Rajkumar SV, et al.”
BackgroundDong, G., Mao, L., Huang, B., Gamalo-Siebers, M., Wang, J.-Z., Yu, G.-L., & Hoaglin, D. (2020) · Journal of Biopharmaceutical Statistics · doi:10.1080/10543406.2020.1757692 · Cited by 97
“Examples Example 1: Monoclonal gammopathy of undetermined significance A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older (Kyle et al. 2002).”
BackgroundMultiple myeloma in 16 cats: a retrospective study
Patel, R. T., CÁCERES, A. V., French, A. F., & McManus, P. M. (2005) · Veterinary Clinical Pathology · doi:10.1111/j.1939-165x.2005.tb00059.x · Cited by 96
Pathogenesis and progression of monoclonal gammopathy of undetermined significance
Bladé, J., Rosiñol, L., Cibeira, M. T., & de Larrea, C. F. (2008) · Leukemia · doi:10.1038/leu.2008.203 · Cited by 104
“…of patients 10 years 20 years 25 years Kyle et al. (2004)7 241 17 34 39 Pasqualetti et al. (1997)53 263 15 31 F Cesana et al. (2002)54 1104 14 F F Kyle et al. (2002)31 1384 12 25 30 Montoto et al. (2002)55 434 15 34 F Leukemia S P O T L IG H T Consequently, the evolving MGUS could be considered…”
Delorme, S., & Baur‐Melnyk, A. (2009) · European Journal of Radiology · doi:10.1016/j.ejrad.2009.02.005 · Cited by 96
Increased Serum Free Light Chains Precede the Presentation of Immunoglobulin Light Chain Amyloidosis
Weiss, B. M., Hebreo, J., Cordaro, D. V., Roschewski, M. J., Baker, T. P., Abbott, K. C., & Olson, S. W. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.0892 · Cited by 97
Metadata
- Authors
- Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Offord, J. R., Larson, D. R., Plevak, M. F., & Melton, L. J.
- Affiliations
- Mayo Clinic (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-02-21
- Volume
- 346
- Issue
- 8
- Pages
- 564-569
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2000655497
- Cited by
- 1,475
- References
- 17
- Citations by year
- 2026: 32 · 2025: 51 · 2024: 66 · 2023: 48 · 2022: 62 · 2021: 65 · 2020: 66 · 2019: 56 · 2018: 67 · 2017: 62 · 2016: 59 · 2015: 63 · 2014: 74 · 2013: 87 · 2012: 63
- FWCI
- 23.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA6 2242, P01CA062242)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Internal Medicine › Amyloidosis: Diagnosis, Treatment, Outcomes
- Keywords
- monoclonal gammopathy of undetermined significance, progression to multiple myeloma, prognosis, plasma cell neoplasms, AL amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, plasmacytoma, smoldering multiple myeloma, bone marrow plasma cells, risk prediction
- MeSH terms
- Adult, Aged, Amyloidosis, Follow-Up Studies, Humans, Leukemia, Lymphoid, Lymphoma, Waldenstrom Macroglobulinemia, Middle Aged, Multiple Myeloma, Paraproteinemias, Probability, Prognosis, Risk Factors, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.